QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR

SYDNEY and BEDMINSTER, N.J., Oct. 12 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). "The Patheon relationship represents a major step forward for QRxPharma that rounds out our platform of MoxDuo(TM) products," said Dr. John Holaday, Managing Director and Chief Executive Officer. "Patheon is a well-known manufacturing organisation with proven ability to develop novel formulations of drugs that address global markets. Our goal is to provide physicians and patients with a variety of complementary Dual Opioids(TM) for managing moderate to severe pain. MoxDuo(TM)CR is expected to deliver clinical benefits similar to those clinically demonstrated with MoxDuo(TM)IR (immediate release formulation) - fewer side effects and superior pain relief."The new formulation includes tamper resistant features and is designed to provide 12 hours of pain relief. "We are targeting a twice daily dosage with MoxDuo(TM) CR, and we anticipate our initial Phase 1 studies will begin this year to evaluate the pharmacokinetic profile of this patented formulation," said Holaday. "QRxPharma's most advanced product for treating acute pain, MoxDuo(TM)IR, is now in Phase 3 trials and scheduled for New Drug Application (NDA) filing with the US Food and Drug Administration in 2010. QRxPharma's formulation of MoxDuo(TM)CR is anticipated to complete clinical trials in 2012."The Company's MoxDuo product portfolio includes immediate release, controlled release and intravenous formulations to address pain mana...
Click here to read the whole Article (external link)

QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 24 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and Pink Sheets: QRXPY), announced today a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. ("Nuokang"), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market. The strategic alliance involves Nuokang investing US$5.0 million for a controlling interest in a Hong Kong company that holds a license over two of QRxPharma's lead haemostasis product candidates: Textilinin, an antifibrinolytic agent, and Haempatch(TM), a potent pro-coagulant. The transaction is expected to be completed by mid October 2009. On completion, a minority interest in the Hong Kong company will be held by Venomics Pty Ltd, which is a majority-owned subsidiary of QRxPharma and holds all of the venomics assets of QRxPharma. An affiliated company of Nuokang has also subscribed to a 10% interest in Venomics Pty Limited."We are very pleased to announce the strategic alliance of QRxPharma's venomics program with a leading Chinese biopharmaceutical company that has extensive experience in the development, manufacture and sale of therapeutics derived from snake venoms," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Blood loss in surgery and trauma is a significantly under-served market opportunity, and Nuokang's capabilities and resources will ensure that Textilinin and Haempatch(TM) progress quickly to the clinic."Dr. Holaday further said that he was particularly pleased to have concluded this deal:"This strategic alliance provides a great opportunity to extract value for QRxPharma shareholders from the venomics assets without diverting management's attention away from QRxPharma's main prospect with its Dual Opioid(TM) development programme in t...
Click here to read the whole Article (external link)

MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)

Pain relieving effects of MoxDuo(TM) IR are dose-related with a better safety profile than Percocet® in patients with post-operative pain following total knee replacement SYDNEY, Australia and BEDMINSTER, N.J., Aug. 26 /PRNewswire/ -- QRxPharma Limited (ASX: QRX - News) and (OTCQX: QRXPY) announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery. When compared at equianalgesic doses with Percocet®, the second most widely prescribed opioid in the US, MoxDuo(TM) IR demonstrated greater overall tolerability with substantially fewer incidences of moderate to severe nausea, vomiting, constipation, and hypotension than Percocet®. Scheduled for launch in 2011, MoxDuo(TM) IR targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US."This study serves to reinforce earlier clinical findings that showed improved tolerability and again demonstrates the value of our Dual-Opioid platform as MoxDuo IR opens the therapeutic window for treating patients suffering from acute post-surgical pain," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "We believe the MoxDuo product portfolio, including immediate release, controlled release and intravenous formulations, will significantly improve patient care, providing equal or better analgesia with fewer and/or...
Click here to read the whole Article (external link)

RedChip Announces CEO Interviews and Company Presentations From Its 2009 San Francisco Conference Now Available Online

ORLANDO, Fla., April 8, 2009 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. today announced that videos of the corporate presentations and CEO interviews made by presenting companies at RedChip's 2009 Small-Cap Investor Conference and Health Tech Investment Forum held in San Francisco on March 24, 2009 are now available online. The presentations highlighted the growth strategies, market positioning and strategic objectives for emerging growth companies representing a wide range of sectors including Healthcare, Technology, Alternative Energy, Telecommunications, Energy, Consumer Goods, Business Services, and more. The webcast videos, which were produced by RedChip Small-Cap TV, will be available for at least 90 days and can be accessed via the following link:http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archiveExecutive interviews and/or company presentations are available for the following companies:Bridgeline Software, Inc. (NasdaqCM:BLSW - News); LGL Group, Inc. (NYSE Amex:LGL); Alter NRG Corporation (Other OTC:ANRGF.PK - ...
Click here to read the whole Article (external link)

Discover Emerging Growth Companies At the 2009 RedChip Investor Conference and Health Tech Investment Forum in San Francisco

ORLANDO, Fla., March 11, 2009 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. and Health Tech Investment Forum today announced that the CEOs and executive teams of 30 emerging small-cap and health care technology companies will participate in the 2009 RedChip Companies and Health Tech Investment Forum to be held March 24, 2009 in San Francisco. The event will feature a dedicated presentation track for health care technology companies and a second track for emerging growth companies representing a diverse range of sectors, including Alternative Energy, Telecommunications, Technology, Energy, Consumer Goods, Business Services, and more. The one-day event will take place from, from 8 a.m. to 6 p.m. PDT on March 24th at the Le Meridien San Francisco hotel in the Financial District (333 Battery Street). The event will also feature an opening keynote presentation entitled ``Health Care Information Technology: Center Stage in Health Care's Future,'' by David J. Brailer, MD, PhD, Chairman, Health Evolution Partners. In 2004, Dr. Brailer was appointed by President George W. Bush as the first National Coordinator for Health Information Technology. In this role, he developed and led the nation's strategy for ushering health care into the digital era. Dr. Brailer is recognized as a leader in the strategy and financing of quality and efficiency in health care, with a particular emphasis on health information technology and health systems management.In addition, there will be three panel discussions addressing private equity and investment trends in health care IT, including ``Healthcare Technology Investment: Trends and Outlook,'' ``Corporate Consolidation & Acquisition Strategies,'' and ``Private Equity: Healthcare Technology Insights & Activity.''RedChip investor conferences are a nationally known forum for emerging small-cap companies to present their ...
Click here to read the whole Article (external link)